Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making.
Classification and staging of hepatocellular carcinoma in a way that allows optimal treatment selection is challenging. This article summarizes some of the classification and staging schemes and discusses the conceptual framework that guides optimal treatment selection for each patient. The article does not exhaustively discuss each staging system proposed in the last three decades, but rather reviews the most commonly used staging systems, evaluates the rationale behind some of the newer staging systems, and compares them focusing on their use in clinical decision-making, notably choice of therapy.
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA.
Benyam D
BD
Addissie
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: roberts.lewis@mayo.edu.
Lewis R
LR
Roberts
D055011:Ablation Techniques; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000145:classification / Q000473:pathology* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D003657:Decision Making; D003661:Decision Support Techniques; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000145:classification / Q000473:pathology* / Q000628:therapy; D016031:Liver Transplantation; D009367:Neoplasm Staging / Q000379:methods; D061766:Proton Therapy; D016634:Radiosurgery
D000970:Antineoplastic Agents
Classification; Hepatocellular carcinoma; Treatment selection; Tumor staging